Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
A Florida 503A compounder advertising peptide therapy and weight-loss formulas — with a practitioner-gated catalog and a PCAB claim we could not independently confirm.
This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.
Cre8 Pharmacy (legal name CRE8 Pharmacy Group, LLC) is a patient-specific 503A compounding pharmacy in Coral Springs, FL. It markets to prescribers, and its actual product catalog sits behind a practitioner login — so some specifics can’t be verified from the public site.
Cre8 describes itself as a 503A compounding facility; it does not appear on the FDA Registered Outsourcing Facilities (503B) list [1], consistent with 503A-only, state-regulated operation. Its site has a dedicated page claiming PCAB accreditation [2], but we could not confirm that listing in ACHC’s own accreditation directory [3] — so treat the PCAB claim as stated-but-unverified.
The public site advertises “Peptide Therapy” and “Weight Loss Formulas” as categories, but the specific molecules (e.g., which peptides, semaglutide/tirzepatide) are behind a practitioner login and are not publicly listed [2]. So the peptide/GLP-1 focus is clear at the category level; the exact menu is practitioner-gated.
We found no FDA warning letter for Cre8 in public sources. As a 503A pharmacy it isn’t on the FDA 503B inspection list [1]; primary oversight is Florida’s board of pharmacy. Absence from federal databases is not an exhaustive clean record.
An on-audience 503A peptide/weight-loss compounder. Two honest caveats: the PCAB accreditation is claimed on their site but not confirmable in ACHC’s registry, and the molecule catalog is practitioner-gated, so we can’t independently verify exactly what they compound. (Note: a claim circulating that Cre8 supplies the telehealth brand Hims is not supported by any source we found.)